Specifically, it showed that patients carrying the CTLA4 rs3087243-AG/GG or TAP1 rs1800453-AG genotypes, or the previously mentioned FBXL19 rs10782001-GG, IL23R rs11209026-AG and SLC12A8 rs651630-AA, had a higher risk of developing paradoxical psoriasis during treatment (CTLA4 rs3087243-AG/GG: OR = 0.001, CI95% = 0–0.24, p = 0.012; TAP1 rs1800453-AG: OR = 0.009, CI95% = 0–0.45, p = 0.018) [90]. This evidence concerns the gene FBXL19 and psoriasis.